Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced stage non-small-cell lung cancer

Faculty	Medicine	Year:	2018
Type of Publication:	ZU Hosted	Pages:
Authors:
Journal:	Cancer Management and Research DOVE MEDICAL PRESS LTD	Volume:

Keywords :	Efficacy , safety , crizotinib , patients with anaplastic
Abstract:	Lung cancer is the leading cause of cancer mortality worldwide, despite advances in management, especially with targeted agents and immunotherapy. Numerous oncogenes have been identified that control the growth of these malignancies. Anaplastic lymphoma kinas (ALK) is a tyrosine kinase that develops distorted functioning as a result of chromosomal rearrangement. Crizotinib, a tyrosine kinase inhibitor (TKI), was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of advanced ALK-positive non-small-cell lung cancer (NSCLC). -In NSCLC, crizotinib is a viable treatment option with good response and tolerable toxicity for patients with ALK-positive advanced disease

Author Related Publications

Shereen Mostafa Saleh Elshorbagy, "prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study", PMID: 35506035, 2022 More
Rasha Mohamed Mostafa Hagag, "Prognostic Value of Snail-1and Beta-Catenin Immunostaining in Astrocytoma.", International Journal of Advanced Research (2016), Volume 4, Issue 4, 1055-1066, 2016 More
Rasha Mohamed Mostafa Hagag, "Immunohistochemical expressions of SQSTM1/p62, Beclin-1, and SOX4 in infiltrating duct carcinoma of the breast", Egyptian Journal of Pathology, 2016 More
Shereen Mostafa Saleh Elshorbagy, "Immunohistochemical expressions of SQSTM1/p62, Beclin-1, and SOX4 in infiltrating duct carcinoma of the breast", Egyptian Journal of Pathology, 2016 More